• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

1,022
93
67
64
53

COUNTRY

61
13
11
8
6

CATEGORIES

  • 83
  • 122
  • 65
  • 63
  • 37
  • 33
  • 10
  • 10
  • 12
  • 16

PRICE

558
815
1,664
2,771

PUBLISHED

57
217
576
2,771

PRODUCT TYPE

2,658
94
9
6
2
2

Oncology

(2,771 Products)

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 9th Edition The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 9th Edition - Product Thumbnail Image

The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 9th Edition

The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 9th Edition In nine best-selling editions, Shara Rosen (MBA, RT), has created authoritative market estimates and forecasted growth models...

August 2014
FROM

Companion Diagnostics in Personalized Medicine and Cancer Therapy

Companion diagnostics (CDx) refers to a particular clinical diagnostic test that is under evaluation and is specifically linked to a known drug therapy This linkage could be important in the therapeutic...

June 2014
FROM

Global Breast Cancer Market 2014-2018

About Breast Cancer Breast cancer is characterized by the uncontrolled growth of cancerous cells in the breast tissue. It occurs in both males and females; however, male breast cancer is rare. Histologically,...

June 2014
FROM

Global Non-Melanoma Skin Cancer Market 2014-2018

About Non-melanoma Skin Cancer Non-melanoma skin cancer is one of the most common types of cancer in the world It develops in the upper layers of the skin, but not in melanocytes There are two types...

May 2014
FROM
Therapeutic Class Overview: Newer Oral Anti Androgens – Expanding Role in the Treatment Paradigm of Prostate Cancer Therapeutic Class Overview: Newer Oral Anti Androgens – Expanding Role in the Treatment Paradigm of Prostate Cancer - Product Thumbnail Image

Therapeutic Class Overview: Newer Oral Anti Androgens – Expanding Role in the Treatment Paradigm of Prostate Cancer

XTANDI (Enzalutamide) – Does it have potential to compete against ARN-509 in earlier setting? Zytiga (Abiraterone Acetate) – Ongoing Combination trials creates potential beyond Patent Expiry In recent...

February 2014
FROM

Circulating Tumour Cells (CTCs) and Circulating Nucleic Acids (CNAs) in Research, Clinical & Diagnostics and in Drug R&D: An Integrated Market Study of Developments, Growth Areas and Opportunities

Market findings from this integrated study are based on 'real world' laboratory data, provided by end-users who investigate Circulating Tumour Cells (CTCs) and Circulating Nucleic Acids (CNAs) in the...

May 2014
FROM

Cancer Molecular Diagnostics: Suppliers Market Report 2014

Cancer diagnostics is one of the most dynamic medical fields, reflecting efforts to translate new advances in cancer into improved tests and treatments Increasingly, researchers and clinicians pursue...

February 2014
FROM

Cancer Molecular Diagnostics: Market Developments, Growth Areas and Opportunities 2014

Cancer diagnostics is one of the most dynamic medical fields, reflecting efforts to translate new advances in cancer into improved tests and treatments Increasingly, researchers and clinicians pursue...

February 2014
FROM

Cancer Molecular Biomarkers 2014: A Global Market Study

Technological advances in molecular biology over the last decade are accelerating the development of new nucleic acid diagnostic tests These advances provide opportunities for faster, simpler and more...

March 2014
FROM

Global Ovarian Cancer Market 2014-2018

About Ovarian Cancer and its therapy Ovarian cancer is a condition where a malignancy forms in the ovarian tissue and is caused by uncontrollable cell growth. It is one of the major gynaecological...

June 2014
FROM

Treating Refractory Hematological Malignancies – Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A

The report (ToC) provides an overview of the therapies for Multiple Myeloma (Newly diagnosed - NDMM and relapsed/ refractory - RRMM), unmet need, and limitations of the current standard of care (SoC)...

September 2013
FROM

Global Gynecological Cancers Market 2014-2018

The analysts forecast the Global Gynecological Cancers market to grow at a CAGR of 12.47 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase...

December 2013
FROM

Bladder Cancer: Disease and Pipeline Analysis

This report offers an in-depth market and pipeline analysis of the bladder cancer market. This unique therapeutic assessment provides an overview of the current and future bladder cancer clinical development...

March 2014
FROM
Personalizing Cancer Drugs Trends Personalizing Cancer Drugs Trends - Product Thumbnail Image

Personalizing Cancer Drugs Trends

The report illustrates that understanding of cancer is shifting from a pathology-oriented perspective to a molecular perception Mechanisms responsible for driving cancer continue to emerge in diverse...

January 2014
FROM
Cancer Stem Cell Trends Cancer Stem Cell Trends - Product Thumbnail Image

Cancer Stem Cell Trends

The report illustrates on the growing market for Cancer Stem Cells (CSCs) in the US and Europe The major factors stimulating the growth of the market are the rising affliction of diseases such as cancer...

January 2014
FROM

Oncology Drug Funding 2013

A Comprehensive Intelligence Report on Oncology Drug Funding 2013 is first of its kind funding intelligence report, which provides complete landscape on cancer drug funding starting from early, mid...

September 2013

Brain Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis

This report offers a unique therapeutic assessment and in-depth market and pipeline analysis, providing a view of the glioblastoma multiforme (brain cancer) market not available elsewhere. This reports...

January 2014
FROM

Global Stem Cell Anticancer Therapeutics Market 2012-2016

The analysts forecast the Global Stem Anticancer Therapeutics market to grow at a CAGR of 11 48 percent over the period 2012-2016 Increasing investment in R&D is one of the key factors contributing...

August 2013
FROM

Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments (Influenza, Cervical Cancer, Combinations, Hepatitis, Pneumococcal, MMR, Varicella, Poliovirus , HIB, Others)

Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments The global market for human vaccines experienced strong growth through 2013 with the introduction of new vaccines...

April 2014
FROM

The United States Market for In Vitro Diagnostic Tests

The United States is the world’s largest in vitro diagnostics and nearly half of the global IVD market. While companies seek emerging markets for growth, most healthcare business is generated in the...

March 2014
FROM
Loading Indicator

Our Clients

Photocure ASA Roche Diagnostics Ltd. Abbott Laboratories Ltd. Pfizer, Inc. Novartis AG Becton, Dickinson and Company (BD)